echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xinhua Pharmaceutical's pioglitazone hydrochloride passed the consistency evaluation

    Xinhua Pharmaceutical's pioglitazone hydrochloride passed the consistency evaluation

    • Last Update: 2022-02-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On January 17, Xinhua Pharmaceutical announced that its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co.
    , Ltd.
    ("Xinda Pharmaceutical") received the "Approval Notice for Supplementary Drug Application" for pioglitazone hydrochloride capsules approved and issued by the State Food and Drug Administration.
    , the product consistency evaluation application was approved

    Xinda Pharmaceutical is the first company in China to pass the consistency evaluation of pioglitazone hydrochloride capsules

    Pioglitazone hydrochloride was developed by Takeda Corporation of Japan.
    It was first listed in the United States in July 1999.
    It is mainly used for the treatment of type 2 diabetes.
    It has been listed in Australia, Canada, Japan, Germany, Denmark, Spain and other countries and is widely used

    Relevant data show that in the past three years, the sales of pioglitazone hydrochloride tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have remained above 500 million yuan

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.